Impairment of host immune response against strongyloides stercoralis by human T cell lymphotropic virus type 1 infection.
A large-scale study was undertaken to clarify the prevalence rate of strongyloidiasis in Okinawa, Japan and to evaluate the relationship between strongyloidiasis and infection with human T cell lymphotropic virus type 1 (HTLV-1). The prevalence rate of Strongyloides stercoralis and HTLV-1 infection were 6.3% and 14.0%, respectively. Among 2,185 patients more than 50 years of age, the rate of S. stercoralis infection was significantly higher in patients with HTLV-1 infection compared with patients without HTLV-1 infection. In 252 patients treated with ivermectin, serum IgE levels and peripheral eosinophil counts were significantly lower in HTLV-1 co-infected patients compared with patients without HTLV-1 infection. In addition, the anthelmintic effect was significantly lower in patients with HTLV-1 infection compared with patients without HTLV-1 infection. Our prospective study demonstrated a prevalence rate for strongyloidiasis and HTLV-1 infections, and clearly demonstrated that co-infection with HTLV-1 impaired the immune response against S. stercoralis.
Control and Prevention of Infectious Diseases, Department of Medicine and Therapeutics, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan. h400314@med.u-rykyu.ac.jp
Tetsuo
T
Hirata
Nobufumi
N
Uchima
Kazuto
K
Kishimoto
Osamu
O
Zaha
Nagisa
N
Kinjo
Akira
A
Hokama
Hiroshi
H
Sakugawa
Fukunori
F
Kinjo
Jiro
J
Fujita
D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D015897:Comorbidity; D005260:Female; D015481:HTLV-I Antibodies / Q000097:blood; D015490:HTLV-I Infections / Q000097:blood / Q000453:epidemiology* / Q000276:immunology / Q000821:virology; D015368:Human T-lymphotropic virus 1 / Q000276:immunology / Q000302:isolation & purification / Q000472:pathogenicity; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007223:Infant; D007559:Ivermectin / Q000008:administration & dosage / Q000627:therapeutic use; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011446:Prospective Studies; D012737:Sex Factors; D017171:Strongyloides stercoralis / Q000302:isolation & purification; D013322:Strongyloidiasis / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology
D000871:Anthelmintics; D015481:HTLV-I Antibodies; D007074:Immunoglobulin G; D007559:Ivermectin